Caritas Traegergesellschaft Saarbruecken mbH (CTS) — Clinical Trial Site

39 Registered trials

17 Currently recruiting

Organisation

Caritas Traegergesellschaft Saarbruecken mbH (CTS)

Location

Saarbruecken, Germany

Identifier

ORG-100031022

Address

Rheinstrasse 2, Malstatt, 66113, Germany

Departments

Apotheke
Brustzentrum Saar Mitte
Brustzentrum Saar Mitte des CaritasKlinikums Saarbrücken
Brustzentrum sowie Gynäkologisches Krebszentrum
Caritas Klinikum Saarbrücken St. Theresia
Caritas Klinikum Saarbrücken St. Theresia Kllinikum für Hämatologie und Onkologie
Department of Internal Medicine - Gastroenterology
Department of Internal Medicine Hematology/Oncology
Department of Obstetrics and Gynecology
Department of Otorhinolaryngology
Frauenheilkunde/Brustzentrum Saar Mitte
Frauenklinik
Frauenklinik Brustzentrum
Gastroenterologie/Endokrinologie/Infektiologie/Stoffwechsel- und Ernährungskrankheiten
Gynacology (Klinik fuer Frauenheilkunde/Brustzentrum)
Gynäkologisches Krebszentrum
Hämatologie und Onklogie
Hematology
Internal Medicine - Gastroenterology
Internal Medicine and Gastroenterology
Klinik fuer Frauenheilkunde/Brustzentrum Saar Mitte
Klinik für Frauenheilkunde
Klinik für Frauenheilkunde Gynäkologisches Krebszentrum
Klinik für Frauenheilkunde/Brustzentrum Saar Mitte
Klinik für Gastroenterologie
Klinik für Hämatologie und Onkologie
Med. Klinik-Gastroenterologie, Endokrinologie, Infektiologie
Medizinische Klinik - Gastroenterologie, Endokrinologie, Infektiologie
Schwerpunkt Spezielle Gynäkologische Onkologie, Brustkrebszentrum, Gynäkologisches Krebszentrum
Women's Clinic

Clinical trials at this site (39)

Search interface

HOVON 156 AML: Treatment for acute myeloid leukemia (AML) or myelodysplastic syndrome with a FLT3 mutation with gilteritinib or midostaurin … Ended

2022-502478-18-00 Acute Myeloid Leukemia (AML) 4 2019-12-20
Phase III study of pembrolizumab for high-risk early-stage ER+/HER2– breast cancer Ended

2023-506921-12-00 ER+/HER2- Breast Cancer 5 2018-12-27
DANTE / FLOT8 A randomized, open-label Phase II/III efficacy and safety study of atezolizumab in combination with FLOT versus FLOT alone in … Ended

2024-514945-12-00 locally advanced resectable adenocarcinoma of the oesop 10 2018-09-03
Olaparib as adjuvant treatment in patients with germline BRCA mutated high risk HER2negative primary breast cancer. Ended

2024-511096-15-00 Breast Cancer 5 2014-08-01
A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Letrozole Compared to Letrozole Alone in Postmenopausal Wom… Ended

2024-512848-30-00 HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE BREAST CANCER 4 2024-11-12
A Phase 2, Multicenter, Open-Label Study of DKN-01 in Combination with Tislelizumab ± Chemotherapy as First Line or Second-Line Therapy in A… Ended

2023-504940-32-00 Gastric cancer 4 2023-10-13
A randomized phase III non-inferiority trial assessing lenalidomide, bortezomib and dexame-thasone induction therapy with either intravenous… Ended

2024-516300-41-00 Multiple Myeloma 5 2023-03-07
RegoNivo vs Standard of Care Chemotherapy in AGOC (INTEGRATEIIb) Ended

2023-505441-69-00 refractory, advanced gastro-oesophageal cancer 5 2022-05-17
CIRCULATE Ended

2023-506715-18-00 colon cancer stage II, rectal cancer stage II 5 2019-12-04
First-line chemotherapy plus pembrolizumab and olaparib for BRCA nonmutated advanced EOC Ended

2022-502124-52-00 Advanced epithelial ovarian cancer 5 2018-12-18
A Randomized, Double-Blind, Phase III Clinical Trial of Neoadjuvant Chemotherapy with Atezolizumab or Placebo in Patients with Triple-Negati… Ended

2023-508472-11-00 Patients with early breast cancer 5 2018-06-13
Phase 3 Trial of Maintenance with Selinexor/ Placebo After Combination Chemotherapy for Patients with Advanced or Recurrent Endometrial Canc… Ended

2024-513167-68-00 endometrial cancer 5 2017-11-29
A Phase III, Randomized, Double-blind Study to Evaluate Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy as Neoadjuvant Therapy … Ended

2022-501382-49-00 Triple Negative Breast Cancer (TNBC) 5 2017-03-07
Ramucirumab plus Irinotecan / Leucovorin / 5-FU versus Ramucirumab plus Paclitaxel in patients with advanced or metastatic adenocarcinoma of… Ended

2024-512934-14-00 advanced or metastatic adenocarcinoma of the stomach or 5 2016-11-07
A study to investigate the efficacy and safety of luveltamab tazevibulin versus IC chemotherapy in women with ovarian cancer (including fall… Ended

2024-512477-27-00 Advanced Epithelial Ovarian Cancer (including Fallopian 4